Funding Newsletter
May 2019

NIH NOTICES

Notification of Upcoming Change in Federal-wide Unique Entity Identifier Requirements (NOT-OD-19-098)
National Institutes of Health

Notice of Preapplication Webinar for Administrative Supplements for Activities to Promote Human Immune-Representing Oncology Models (NOT-CA-19-040)
National Cancer Institute

Pre-Application Webinar for RFA-CA-19-035, Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (R01 Clinical Trial Required) (NOT-CA-19-041)
National Cancer Institute

Notice of Correction to Eligibility Information in PAR-18-947 "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)" (NOT-CA-19-042)
National Cancer Institute

Notice of Upcoming Webinar for the NCI Office of Cancer Survivorship (NOT-CA-19-043)
National Cancer Institute

National Institutes of Health

Notice of Intent to Publish: Funding Opportunity Announcement for Human Immune-Representing Oncology Models for Immuno-Oncology Research (R33 Clinical Trial Optional) (NOT-CA-19-047)
National Cancer Institute

Notification of Correction to Award Information in RFA-CA-19-040 "Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) (NOT-CA-19-044)
National Cancer Institute

Notice of Correction to Award Information in RFA-CA-19-041 "Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)" (NOT-CA-19-045)
National Cancer Institute

MAY DEADLINES

Foundation and Other Sources

Alex's Lemonade Stand Foundation (ALSF) 'A' Awards
Deadline: 5/20/2019
https://www.alexslemonade.org/sites/default/files/2019_a-award_guidelines_final_0.pdf

About: The 'A' Award is designed for the early independent career scientist who wants to establish a career in pediatric oncology research. The ideal candidate has an original project, can demonstrate outstanding career development support from the institution, and has a strong future commitment to pediatric cancer investigation. These awards are open to MD, MD/PhD and PhD applicants who are within 5 years of their first faculty appointment as an Assistant Professor.

Period of Support: 4 years
Funds/Direct Costs: Direct costs are limited to $200,000 per year.
Program Contact: Judy Oliver
(610) 649-3034
grants@alexslemonade.org
Alex's Lemonade Stand Foundation (ALSF)

Reach Grants

**Deadline:** 5/20/2019

https://www.alexslemonade.org/sites/default/files/2019_reach_guidelines_final_0.pdf

**About:** This award is designed to move hypothesis-driven research toward the clinic. A successful application will identify an unmet clinical need relevant to the care of patients with pediatric cancer and describe how the work performed will allow for the translation of hypothesis-driven research to the clinic, keeping broader clinical testing and implementation in view.

**Period of Support:** 2 years

**Funds/Direct Costs:** Direct costs are limited to $125,000 per year

**Program Contact:** Brenda Delarm  
(866) 333-1213  
grants@alexslemonade.org

---

Hematology/Oncology Pharmacy Association

Early Career Research Grant

**Letter of Intent Deadline:** 5/24/2019

**Full Application Deadline:** 9/13/2019

http://www.hoparx.org/research/early-career-research-grant

**About:** The HOPA Early Career Research Grant (ECR) will provide funding to promising investigators early in their career to encourage and promote quality basic and preclinical translational lab-based research in oncology among HOPA members. The purpose of this award is to fund United States based pharmacists within the first 7 years post completion of formal training who have not yet attained R21 level funding.

**Period of Support:** 2 years

**Funds/Direct Costs:** $50,000 for the entire period.

**Program Contact:** Andrea Dodd  
adodd@hoparx.org

---

National Cancer Institute

Innovative Research in Cancer Nanotechnology (IRCN) (R01)

**Deadline:** 05/23/2019


**About:** This Funding Opportunity Announcement (FOA) encourages applications for the development of innovative research projects in cancer nanotechnology. This initiative, to be known as Innovative Research in Cancer Nanotechnology (IRCN), is a component of a broader program that is the NCI Alliance for Nanotechnology in Cancer.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to $450K in direct costs per year

**Program Contact:** Christopher Hartshorn  
(240) 781-3315  
christopher.hartshorn@nih.gov

---

Multiple Institutes, including the National Cancer Institute

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)

**Deadline:** 05/25/2019


**About:** The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to enhance predoctoral and postdoctoral research training, including short-term research training, and help ensure that a diverse and highly trained workforce is available to meet the needs of the Nation’s biomedical, behavioral, and clinical research agenda.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Susan E. Lim  
(240) 276-5472  
lims@mail.nih.gov

---

Program Announcements (PA)

National Cancer Institute

Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01)

**Deadline:** 05/09/2019


**About:** This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to $500,000 in direct costs per year

**Program Contact:** Robert J. Nordstrom  
(240) 276-5934  
nordstrr@mail.nih.gov
Multiple Institutes, including the National Cancer Institute
Intervention Research to Improve Native American Health (R01)
Deadline: 05/14/2019

About: The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data; merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Shobha Srinivasan
(240) 276-6938
ss688k@nih.gov

National Cancer Institute
Cancer Research Education Grants Program - Research Experiences (R25)
Deadline: 05/25/2019

About: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This FOA will support creative educational activities with a primary focus on Research Experiences.

Period of Support: Up to 5 years
Funds/Direct Costs: $300,000 direct costs per year
Program Contact: Jeannette Korczak
(240) 276-5630
korczakj@mail.nih.gov

National Cancer Institute
Cancer Research Education Grants Program - Curriculum or Methods Development (R25)
Deadline: 05/25/2019

About: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This FOA will support creative educational activities with a primary focus on Curriculum or Methods Development.

Period of Support: Up to 2 years
Funds/Direct Costs: $150,000 direct costs per year
Program Contact: Jeannette Korczak
(240) 276-5630
korczakj@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Perception and Cognition Research to Inform Cancer Image Interpretation (R01)
Deadline: 05/30/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Todd Horowitz
(240) 276-6963
todd.horowitz@nih.gov

National Cancer Institute
Perception and Cognition Research to Inform Cancer Image Interpretation (R21)
Deadline: 05/30/2019

About: The NIH Research Education Program (R21) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R21 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This FOA will support creative educational activities with a primary focus on Research Experiences.
About: The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.  

Period of Support: Up to 2 years  
Funds/Direct Costs: $275,000 direct costs for entire period of support  
Program Contact: Todd Horowitz  
(240) 276-6963  
todd.horowitz@nih.gov  

National Cancer Institute  
Cancer Research Education Grants Program - Courses for Skills Development (R25)  
Deadline: 05/25/2019  
About: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This FOA will support creative educational activities with a primary focus on Courses for Skills Development.  
Period of Support: Up to 5 years  
Funds/Direct Costs: $300,000 direct costs per year  
Program Contact: Jeannette Korczak  
(240) 276-5630  
korczakj@mail.nih.gov  

Request for Applications (RFA)  

National Cancer Institute  
The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24)  
Deadline: 5/22/2019  
About: The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to create Pharmacokinetics Resource Laboratories (PK Laboratories) that will support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratories will be expected to organize specimen collection and subsequent analysis of pharmacokinetic endpoints, drug-drug interactions, cytochromes P450 (CYP) interactions, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents.  
Period of Support: 6 Years  
Funds/Direct Costs: Application budget requests are limited to $320,000 (direct costs) per year.  
Program Contact: S. Percy Ivy  
(240) 276-6107  
ivyp@ctep.nci.nih.gov  

National Cancer Institute  
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)  
Deadline: 05/28/2019  
About: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.  
Period of Support: Up to 3 years  
Funds/Direct Costs: Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year.  
Program Contact: Tony Dickherber  
(301) 547-9980  
dickherberaj@mail.nih.gov  

Multiple Institutes, including the National Cancer Institute  
Predoctoral Training in Advanced Data Analytics for Behavioral and Social Sciences Research (BSSR) - Institutional Research Training Program [T32]  

(240) 276-6107  
ivyp@ctep.nci.nih.gov
**Deadline:** 5/25/2019  

**About:** This FOA solicits applications for new Behavioral and Social Sciences Research (BSSR) predoctoral training programs that focus on innovative computational and/or data science analytic approaches and their incorporation into training for the future BSSR health research workforce. The vision of the Advanced Data Analytics for BSSR training program is to support the development of a cohort of specialized predoctoral candidates who will possess advanced competencies in data science analytics to apply to an increasingly complex landscape of behavioral and social health-related big data.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited, but each institutional training program will be asked to appoint up to 5 trainees annually. Budgets need to reflect the actual needs of the proposed project.  
**Program Contact:** Susan Perkins  
(240) 276-5630  
perkinsu@mail.nih.gov

---

**National Cancer Institute**  
**Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)**  
**Deadline:** 05/28/2019  

**About:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

**Period of Support:** Up to 3 years  
**Funds/Direct Costs:** Direct costs are limited to $300,000 per year.

**Program Contact:** Tony Dickherber  
(301) 547-9980  
dickherberaj@mail.nih.gov

---

**Intramural Funding Opportunities**

**Massey Cancer Center**  
**Ancillary Studies to Advance Knowledge on Biological and/or Behavioral Factors Relevant to Cancer (ABBC Award)**  
**Deadline:** 5/24/2019  

**About:** The intent of the ABBC Award is (1) to support the addition of behavioral, social or economic endpoints to studies where the primary focus is on biological or clinical endpoints or (2) to support the addition of biological or clinical data endpoints to studies where the primary endpoints are on behavioral, social, or economic measures. The ABBC Award is also intended to encourage multidisciplinary and inter-programmatic collaborations among members of Massey’s research programs, especially collaborations involving members of the Cancer Prevention and Control program.
**Period of Support**: 1 year  
**Funds/Direct Costs**: $25,000 for entire period  
**Program Contact**: Morgan Hembarsky  
(804) 828-3114  
mhembarsky@vcu.edu

---

**JUNE/JULY DEADLINES**

**Foundation and Other Sources**

**THRIVE**  
**HESI THRIVE Grant Program**  
**Deadline**: 7/1/2019  
[http://hesithrive.org/guidelines/](http://hesithrive.org/guidelines/)  
**About**: The THRIVE grant program is designed to provide seed funding to investigators for the testing of initial hypotheses and collecting of preliminary data to help secure long-term funding by the National Institutes of Health and/or other major granting institutions.  
**Period of Support**: Up to 2 years  
**Funds/Direct Costs**: Range of $20,000-$50,000  
**Program Contact**: THRIVE  
research@hesithrive.org

**Lung Cancer Research Foundation**  
**Pilot Grant Program**  
**Deadline**: 6/14/2019  
[http://www.lungcancerresearchfoundation.org/research/funding-opportunities/lcrf-pilot-grant-program](http://www.lungcancerresearchfoundation.org/research/funding-opportunities/lcrf-pilot-grant-program)  
**About**: The Lung Cancer Research Foundation’s annual pilot grant program provides funding for research focused on the prevention, diagnosis, treatment and cure of lung cancer. The goal of the program is to fund innovative projects across the spectrum of basic, translational, and clinical research.  
**Period of Support**: 2 years  
**Funds/Direct Costs**: Direct costs are limited to $75,000 per year. No indirects allowed.  
**Program Contact**: LCRF office  
(212) 588-1580  
grants@lcrf.org

**When Everyone Survives (WES) Leukemia Research Foundation**  
**Request for Proposals in Leukemia Research**  
**Deadline**: 6/1/2019  
[https://www.wheneveryone survivesto.org/grant_application](https://www.wheneveryone survivesto.org/grant_application)  
**About**: This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) to solicit innovative research in leukemia. Grants of $50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia. The WES Foundation is supports leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of “When Everyone Survives”.  
**Period of Support**: 1 year  
**Funds/Direct Costs**: $50,000 total costs for entire period  
**Program Contact**: WES Foundation  
(770) 595-3573  
contact@wheneveryonesurvives.org

**The Hope Foundation for Cancer Research**  
**SWOG/Hope Foundation Impact Award**  
**LOI Deadline**: 7/1/2019  
**Full Application Deadline**: 9/1/2019  
**About**: The SWOG/ Hope Foundation Impact Award is a funding program from The Hope Foundation that encourages novel and innovative SWOG research by supporting early and conceptual stages of these projects. The work proposed should use resources from completed SWOG trials or be directly translatable to clinical trials in SWOG and the NCTN in the foreseeable future.  
**Period of Support**: Up to 2 years  
**Funds/Direct Costs**: $250,000 total costs for the entire period  
**Program Contact**: Johanna Horn  
(734) 998-7150  
jo@thehopefoundation.org

**Children’s Leukemia Research Association (CLRA) Research Grants**  
**Deadline**: 06/30/2019  
[https://www.childrensleukemia.org/research-grants-summary.asp](https://www.childrensleukemia.org/research-grants-summary.asp)  
**About**: CLRA is on the leading edge of research, stimulating and facilitating the opportunity for new avenues of investigation. They fund research grants for doctors who are conducting the most promising research into leukemia, in the hopes of isolating the causes and finding a cure for this dreaded disease.  
**Period of Support**: 1 year  
**Funds/Direct Costs**: $30,000 total costs for entire period of support  
**Program Contact**: CLRA  
(516) 222-1944  
info@childrensleukemia.org
**Damon Runyon Cancer Research Foundation**
**Damon Runyon-Rachleff Innovation Award**

**Deadline:** 7/1/2019  
[https://www.damonrunyon.org/for-scientists/application-guidelines/innovation](https://www.damonrunyon.org/for-scientists/application-guidelines/innovation)

**About:** The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.

**Period of Support:** Up to 4 years

**Funds/Direct Costs:** $200,000 direct costs per year

**Program Contact:** Award Programs  
(212) 455-0520  
awards@damonrunyon.org

---

**Program Announcements (PA)**

**National Cancer Institute**
**Leveraging Population-based Cancer Registry Data to Study Health Disparities (R21)**

**Deadline:** 06/16/2019  

**About:** The goal of this Funding Opportunity Announcement (FOA) is to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000

**Program Contact:** Kathleen Cronin  
(240) 276-6836  
cronink@mail.nih.gov

---

**National Cancer Institute**
**Integration of Individual Residential Histories into Cancer Research (R01)**

**Deadline:** 06/05/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support substantive investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Zaria Tatalovich  
(240) 276-6976  
tatalovichzp@mail.nih.gov

---

**National Cancer Institute**
**The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21)**

**Deadline:** 06/16/2019  

**About:** The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in naïve and drug resistant cancers.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** $275,000 direct costs for entire period of support

**Program Contact:** Konstantin Salnikow  
(240) 276-6230  
salnikok@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**
**Biology of Lung, and Head and Neck Prenoeplasias (R21 - Clinical Trial Not Allowed)**

**Deadline:** 06/15/2019  

**About:** This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** Application budgets are limited to $275,000 in direct costs per year

**Program Contact:** Long Nguyen  
(240) 276-5807  
long.nguyen@nih.gov

---

**National Cancer Institute**
**Multilevel Interventions in Cancer Care Delivery: Follow-up to Abnormal Screening Tests (R01 Clinical Trial Optional)**

**Deadline:** 06/05/2019  
About: This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.

Period of Support: Up to 5 years

Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Program Contact: Erica S. Breslau  
(240) 276-6773  
breslaue@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01)
Deadline: 06/05/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults.

Period of Support: Up to 2 years

Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.

Program Contact: Erica S. Breslau  
(240) 276-6773  
breslaue@mail.nih.gov

National Cancer Institute
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21 Clinical Trial Optional)
Deadline: 06/16/2019

About: The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.

Period of Support: Up to 2 years

Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.

Program Contact: Michelle Mollica  
(240) 276-7621  
michelle.mollica@nih.gov

Multiple Institutes, including the National Cancer Institute
Palliative Care Needs of Individuals with Rare Advanced Diseases and Their Family Caregivers (R21 Clinical Trial Optional)
Deadline: 06/05/2019

About: This funding opportunity announcement (FOA) seeks to expand knowledge and increase the evidence base for palliative care (PC) in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.

Period of Support: Up to 2 years

Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.

Program Contact: Michelle Mollica  
(240) 276-7621  
michelle.mollica@nih.gov

National Cancer Institute
Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R01 Clinical Trial Optional)
Deadline: 06/05/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to: identify new, information technology (IT)-enabled delivery models that support...
systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; test the effectiveness of these new delivery models, and their components, in a variety of oncology practice settings, especially those serving under-served populations; and evaluate the sustainability and scalability of these new delivery models.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Gurvaneet S. Randhawa
(240) 276-6940
gurvaneet.randhawa@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional)**

**Deadline:** 06/05/2019


**About:** This funding opportunity announcement (FOA) seeks to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Wen-Ying Sylvia Chou
(240) 276-6954
chouws@mail.nih.gov

---

**National Cancer Institute**

**Early-life Factors and Cancer Development Later in Life (R03)**

**Deadline:** 06/16/2019,


**About:** The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** $100,000 direct costs per year

**Program Contact:** Somdat Mahabir
(240) 276-6941
mahabir@mail.nih.gov

---

**National Cancer Institute**

**Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)**

**Deadline:** 06/05/2019


**About:** Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to
$499,999 (maximum) in direct costs per year

Program Contact: Anne Menkens
(240) 276-6510
menkensa@mail.nih.gov

National Cancer Institute
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 - Clinical Trial Not Allowed)
Deadline: 06/05/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Tram Kim Lam
(240) 276-6967
Tram.Lam@nih.gov

Multiple Institutes, including the National Cancer Institute
Exploratory/Developmental Clinical Research Grants in Obesity (R21 Clinical Trial Optional)
Deadline: 06/16/2019

About: This Funding Opportunity Announcement (FOA) encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children.

Period of Support: Up to 2 years
Funds/Direct Costs: Application budgets are limited to $275,000 in direct costs per year.
Program Contact: Tanya Agurs-Collins
(240) 276-6956
collinsta@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01)
Deadline: 06/05/2019

About: The purpose of this funding opportunity announcement (FOA) is twofold: 1). to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2). to understand the underlying mechanisms of their action(s), and variability in responses to these interventions.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Gabriela Riscuta
Multiple Institutes, including the National Cancer Institute
Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations
Deadline: 06/05/2019

About: This Funding Opportunity Announcement (FOA) invites applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g. screening recommendations proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Erica Breslau
(240) 276-6773
breslaue@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)
Deadline: 06/16/2019

About: The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual’s chronic pain experience.

Period of Support: 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Sean Hine
(240) 276-6291
hines@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Biobehavioral Basis of Chronic Paint (R01 Clinical Trial Optional)
Deadline: 06/05/2019

About: The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Ann O’Mara
(240) 276-7050
omaraa@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Research Project Grant (Parent R01)
Deadline: 06/05/2019

About: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Crystal Wolfrey
(240) 276-6277
wolfreyc@mail.nih.gov

National Cancer Institute
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)
Deadline: 06/16/2019

About: This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to
the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. **Period of Support:** Up to 2 years **Funds/Direct Costs:** The combined budget for direct costs for the entire project period may not exceed $275,000. **Program Contact:** Nonniekaye Shelburne  
(240) 276-6897  
nshelfburne@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)**  
**Deadline:** 06/12/2019  
**About:** The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Award budgets are composed of salary and other program-related expenses, as described in announcement.  
**Program Contact:** Susan Lim  
(240) 276-5588  
lims@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional)**  
**Deadline:** 06/05/2019  
**About:** The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Diane St. Germain  
(240) 276-6915  
moserr@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Leveraging Population-based Cancer Registry Data to Study Health Disparities (R01)**  
**Deadline:** 06/05/2019  
**About:** The goal of this Funding Opportunity Announcement (FOA) is to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer. Specifically, this FOA will support the study of factors...
influencing observed health disparities within the framework of population-based cancer registries by the inclusion of data not routinely collected by or linked to the registries.

**Period of Support**: Up to 5 years

**Funds/Direct Costs**: Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact**: Kathleen Cronin  
(240) 276-6836  
cronink@mail.nih.gov

---

**National Cancer Institute**

**Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)**

**Deadline**: 06/05/2019


**About**: The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. This FOA encourages the design of research projects that utilize the following phases of discovery research: 1) assay development specifically designed for immunoncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads; 2) screen implementation for immunomodulatory targets to identify initial screening hits; 3) hit validation through secondary orthogonal and counter screening assays, and hit prioritization; and 4) hit-to-lead optimization.

**Period of Support**: Up to 4 years

**Funds/Direct Costs**: Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact**: Sundar Venkatachalam  
(240) 276-7304  
sundarv@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**Assay development and screening for discovery of chemical probes or therapeutic agents (R01)**

**Deadline**: 06/05/2019


**About**: Through this funding opportunity announcement (FOA), NIH wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes; and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.

**Period of Support**: Up to 4 years

**Funds/Direct Costs**: Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact**: Houston Baker  
(240) 276-5908  
bakerhou@mail.nih.gov

---

**National Cancer Institute**

**Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)**

**Deadline**: 6/5/2019


**About**: This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider’s recommendation of the adolescent human papillomavirus (HPV) vaccine.

**Period of Support**: Up to 5 years

**Funds/Direct Costs**: Application budgets should reflect the actual needs of the proposed project.

**Program Contact**: Sarah Kobrin  
(240) 276-6931  
kobrins@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01 Clinical Trial Optional)**

**Deadline**: 06/05/2019


**About**: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status.

**Period of Support**: Up to 5 years

**Funds/Direct Costs**: Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact**: Suzanne Forry  
(240) 276-5922  
forrysccs@mail.nih.gov

---

**National Cancer Institute**

**Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required)**

**Deadline**: 06/28/2019


**About**: This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution
therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools.

**Period of Support**: Up to 3 years

**Funds/Direct Costs**: Application budgets are limited to $500,000 in direct costs per year.

**Program Contact**: Lori A. Henderson  
(240) 276-5930  
hendersonlori@mail.nih.gov

---

**National Cancer Institute**  
**NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional)**  
**Deadline**: 06/28/2019  

**About**: This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

**Period of Support**: Up to 2 years  
**Funds/Direct Costs**: A budget for direct costs of up to $50,000 per year may be requested.

**Program Contact**: Crystal Wolfrey  
(240) 276-6277  
wolfreyc@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R01 Clinical Trial Optional)**  
**Deadline**: 6/13/2019  

**About**: The purpose of this Funding Opportunity Announcement (FOA) is to provide support for highly innovative and promising intervention research designed to improve smoking cessation outcomes among socioeconomically disadvantaged populations.

**Period of Support**: Up to 5 years  
**Funds/Direct Costs**: Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact**: Yvonne Hunt  
(240) 276-6975  
huntym@mail.nih.gov

---

**National Cancer Institute**  
**Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)**  
**Deadline**: 07/10/2019  

**About**: The purpose of this Funding Opportunity Announcement (FOA) is to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control.

**Period of Support**: Up to 3 years  
**Funds/Direct Costs**: Applicants may request up to $275,000 direct costs for the entire UH2 phase with no more than $200,000 requested in any one year and up to $250,000 direct costs for the UH3 phase per year.

**Program Contact**: Tracy G. Lively  
(240) 276-5944  
livelyt@mail.nih.gov

---

**National Cancer Institute**  
**Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)**  
**Deadline**: 06/05/2019  

**About**: The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation.

**Period of Support**: Up to 5 years  
**Funds/Direct Costs**: Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact**: Frank Perna  
(240) 276-6782  
pernafm@mail.nih.gov

---

**National Cancer Institute**  
**NCI Transition Career Development Award to Promote Diversity (K22 No Independent Clinical Trials)**  
**Deadline**: 06/12/2019  

**About**: The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.

**Period of Support**: Up to 3 years  
**Funds/Direct Costs**: Award budgets are composed of salary and other program-related expenses, as described in announcement.
**National Cancer Institute**

**The NCI Transition Career Development Award (K22 Clinical Trial Required)**

**Deadline:** 07/12/2019


**About:** This Funding Opportunity Announcement (FOA) supports an NCI program that facilitates the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Application budgets are composed of salary and other program-related expenses as described in announcement.

**Program Contact:** Sonia Jakowlew  
(240) 276-5630  
jakowles@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 Clinical Trial Optional)**

**Deadline:** 06/05/2019


**About:** The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Miguel R. Ossandon  
(240) 276-5714  
ossandom@mail.nih.gov

---

**National Cancer Institute**

**Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)**

**Deadline:** 06/05/2019


**About:** Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Brandy Heckman-Stoddard  
(240) 276-7048

---

**National Cancer Institute**

**Advancing the Science of Geriatric Palliative Care (R21 Clinical Trial Optional)**

**Deadline:** 06/16/2019


**About:** This Funding Opportunity Announcement (FOA) encourages exploratory or developmental research grant applications to develop new tools, methods, and models focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Ann M. O'Mara  
(240) 276-7050  
omaraa@mail.nih.gov

---

Program Contact: Abigail Soyombo  
(240) 276-6553  
Abigail.Soyombo@nih.gov
About: The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD).

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to less than $500,000 in direct costs per year.

**Program Contact:**
Lori A. Henderson  
(240) 276-5930  
hendersonlori@mail.nih.gov

---

**National Cancer Institute**

**Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01)**

**Deadline:** 06/05/2019


**About:** Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy to patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** $499,999 direct costs per year

**Program Contact:** Anne Menkens  
(240) 276-6510  
menkensa@mail.nih.gov

---

**National Cancer Institute**

**Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21)**

**Deadline:** 6/13/2019


**About:** This Funding Opportunity Announcement (FOA) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** $275,000 direct costs for entire period of support

**Program Contact:** Kelly Blake  
(240) 281-5934  
kelly.blake@nih.gov

---

**National Cancer Institute**

**Basic Research in Cancer Health Disparities (R01)**

**Deadline:** 06/18/2019


**About:** This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Jennifer Isaacs  
(240) 276-6251  
jennifer.isaacs@nih.gov

---

**National Cancer Institute**

**Basic Research in Cancer Health Disparities (R21)**

**Deadline:** 06/18/2019


**About:** This Funding Opportunity Announcement (FOA) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** $275,000 direct costs for entire period of support

**Program Contact:** Kelly Blake  
(240) 281-5934  
kelly.blake@nih.gov
encourages grant applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support  
**Program Contact:** Jennifer Isaacs  
(240) 276-6251  
jennifer.isaacs@nih.gov

---

**National Cancer Institute**  
**U.S. Tobacco Control Policies to Reduce Health Disparities (R21)**  
**Deadline:** 06/13/2019  
**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support  
**Program Contact:** Bob Vollinger  
(240) 276-6919  
bob.vollinger@nih.gov

---

**National Cancer Institute**  
**Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21)**  
**Deadline:** 06/18/2019  
**About:** This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible junior investigators and Early Stage Investigators from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support  
**Program Contact:** Abigail Soyombo  
(240) 276-6553  
abigail.soyombo@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional)**  
**Deadline:** 06/05/2019  
**About:** The purpose of this Funding Opportunity Announcement (FOA) is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Geraldina Dominguez  
(301) 496-3204  
domingug@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Precision Imaging of Oral Lesions (R01 - Clinical Trial Not Allowed)**  
**Deadline:** 06/05/2019  
**About:** The intent of this Funding Opportunity Announcement (FOA) is to advance the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Shane Woodward  
(240) 276-6303  
woodwars@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed)**  
**Deadline:** 06/03/2019  
**About:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the
scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets should not exceed $499,999 direct costs per year  
**Program Contact:** Jennifer Strasburger  
(240) 276-6230  
strasbuj@mail.nih.gov

---

**National Cancer Institute**  
**Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)**  
**Deadline:** 06/14/2019  
**About:** The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets for direct costs up to $500,000 per year may be requested  
**Program Contact:** Nancy Boudreau  
(240) 276-6702  
nancy.boudreau@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)**  
**Deadline:** 06/10/2019  
**About:** This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project  
**Program Contact:** David Berrigan  
(240) 276-6752  
berrigand@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)**  
**Deadline:** 06/16/2019  
**About:** This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Direct costs are limited to $275,000 per year  
**Program Contact:** Carol Perry  
(240) 276-6282  
perryc@nci.nih.gov

---

**National Cancer Institute**  
**Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21)**  
**Deadline:** 06/16/2019  
**About:** This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.

**Period of Support:** 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support  
**Program Contact:** Frank Perna  
(240) 276-6782  
pernafm@mail.nih.gov

---

**National Cancer Institute**  
**Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)**  
**Deadline:** 06/05/2019  
**About:** This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications
should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.

**Period of Support**: Up to 5 years

**Funds/Direct Costs**: Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact**: Frank Perna
(240) 276-6782
pernafm@mail.nih.gov

---

**National Cancer Institute**

**Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)**

**Deadline**: 07/11/2019

**About**: This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies and blood biospecimens utilized as “liquid biopsies.”

**Period of Support**: Up to 5 years

**Funds/Direct Costs**: Application budgets limited to $250,000 direct costs per year

**Program Contact**: Abhi Rao
(240) 276-5715
abhi.rao@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01)**

**Deadline**: 06/05/2019

**About**: The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.

**Period of Support**: Up to 5 years

**Funds/Direct Costs**: Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact**: Lynn Adams
(301) 594-8911
lynn.adams@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)**

**Deadline**: 06/16/2019

**About**: The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

**Period of Support**: Up to 2 years

**Funds/Direct Costs**: Application budgets are limited to $275,000 in direct costs per year

**Program Contact**: Miguel R. Ossandon
(240) 276-5714
ossandom@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)**

**Deadline**: 06/16/2019

**About**: The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

**Period of Support**: Up to 2 years

**Funds/Direct Costs**: Application budgets are limited to $275,000 in direct costs per year

**Program Contact**: Karen Kehl
(301) 594-8010
kehlka@nih.gov
opportunity announcement (FOA) is to encourage submissions of Exploratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Miguel R. Ossandon
(240) 276-5714
ossandom@mail.nih.gov

---

Multiple Institutes, including the National Cancer Institute
Bioengineering Research Grants (BRG) [R01 Clinical Trial Required]

**Deadline:** 06/05/2019

**About:** The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Houston Baker
(240) 276-5908
bakerhou@mail.nih.gov

---

Multiple Institutes, including the National Cancer Institute
Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)

**Deadline:** 06/16/2019

**About:** This FOA will support activities proposing to conduct analyses of existing ABCD Study data to accelerate the pace of research on child health and development, including: cross-sectional and/or longitudinal analyses; development of new or advanced statistical methods; and/or integration of multiple data sets with common data elements. Existing data provide unique opportunities to answer novel research questions in a cost-effective way. We also strongly encourage inclusion of statisticians, computational neuroscientists, and interdisciplinary teams to address novel research questions using these data.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Crystal Wolfrey
(240) 276-6277
wolfreyc@mail.nih.gov

---

National Cancer Institute
Biology of Bladder Cancer (R01 Clinical Trial Optional)

**Deadline:** 06/05/2019

**About:** This Funding Opportunity Announcement (FOA) encourages applications investigating the biology and underlying mechanisms of bladder cancer.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Ron Johnson
(240) 276-6250
rjohnso2@mail.nih.gov

---

National Cancer Institute
Biology of Bladder Cancer (R01 Clinical Trial Optional)

**Deadline:** 06/05/2019

**About:** This Funding Opportunity Announcement (FOA) encourages applications investigating the biology and underlying mechanisms of bladder cancer. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Ron Johnson
(240) 276-6250
rjohnso2@mail.nih.gov

---

National Cancer Institute
Microbial-based Cancer Therapy -Bugs as Drugs (R01 Clinical Trial Not Allowed)

**Deadline:** 06/05/2019

**About:** The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current...
interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. 

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Avi Rasooly  
(240) 276-6196  
rasoolya@mail.nih.gov

---

**National Cancer Institute**  
**Microbial-based Cancer Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)**  
**Deadline:** 06/16/2019  
**About:** The overall purpose of this funding opportunity announcement (FOA) is to stimulate exploratory development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularity, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. The FOA also aims to support research into the use of microorganisms for cancer treatment and to complement or synergize with current therapies.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Application budgets are limited to $275,000 per year.  
**Program Contact:** Avi Rasooly  
(240) 276-6196  
rasoolya@mail.nih.gov

---

**National Cancer Institute**  
**Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional)**  
**Deadline:** 07/10/2019  
**About:** This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Sudhir Srivastava  
(240) 276-7028  
srivasts@mail.nih.gov

---

**National Cancer Institute**  
**Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R21 Clinical Trial Not Allowed)**  
**Deadline:** 06/10/2019  
**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.  
**Program Contact:** Young S. Kim  
(240) 276-7115  
yk47s@nih.gov
**NEW**

**National Cancer Institute**  
**Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)**  
**Deadline:** 06/18/2019  

**About:** The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists (M.D.s, D.O.s, Pharm.D.s, nurses with Ph.D.s, or equivalent) trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This FOA allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial to an existing clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** See announcement for details.  
**Program Contact:** Mark Damico  
(240) 276-5639  
damicomw@mail.nih.gov

**National Cancer Institute**  
**Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Optional)**  
**Deadline:** 07/02/2019  

**About:** The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Wendy Wang  
(240) 276-7117  
wangw@mail.nih.gov

**National Cancer Institute**  
**Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional)**  
**Deadline:** 06/19/2019  

**About:** This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme.

**Period of Support:** Up to 3 years  
**Funds/Direct Costs:** Applicants may request a maximum of $800,000 direct costs per year  
**Program Contact:** Tiffany Wallace  
(240) 276-5114  
wallaceti@mail.nih.gov

**National Cancer Institute**  
**Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (R01 Clinical Trial Required)**  
**Deadline:** 6/28/2019  

**About:** This FOA solicits applications that develop and test models of care for adult survivors of cancer who are transitioning from active treatment to follow-up care. Through this FOA, the NCI intends to support multi-level interventions that enhance communication, collaboration, and coordination among oncology and non-oncology providers to improve cancer survivor outcomes.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are limited to $500,000 direct costs per year  
**Program Contact:** Michelle Mollica  
(240) 276-7621  
michelle.mollica@nih.gov

**National Cancer Institute**  
**Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)**  
**Deadline:** 06/11/2019  
**About:** The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** Direct costs are limited to $275,000 over a two year period. No more than $200,000 may be requested in a single year.

**Program Contact:** Juli Klemm  
(301) 480-5778  
juli.klemm@nih.gov

---

**National Cancer Institute**  
**Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)**

**Deadline:** 06/11/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Direct costs are limited to $300,000 per year

**Program Contact:** Juli Klemm  
(301) 480-5778  
juli.klemm@nih.gov

---

**National Cancer Institute**  
**Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)**

**Deadline:** 06/11/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Direct costs are limited to $600,000 per year

**Program Contact:** Juli Klemm  
(301) 480-5778  
juli.klemm@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)**

**Deadline:** 06/20/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed $500,000 direct cost per year.

**Program Contact:** Diane St. Germain  
(240) 276-7082  
dstgermain@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R21 Clinical Trial Not Allowed)**

**Deadline:** 07/11/2019  

**About:** This R21 NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of pain target discovery and validation projects. These studies may involve considerable risk but may lead to a breakthrough in a pain treatment.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Ann O’Mara  
(240) 276-7050
Multiple Institutes, including the National Cancer Institute
Tobacco Regulatory Science (R01 Clinical Trial Optional)
Deadline: 07/19/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).

Period of Support: Up to 3 years
Funds/Direct Costs: Application budgets are limited to $300,000 in direct cost per year.
Program Contact: Rachel Grana Mayne
(240) 276-5899
granar@nih.gov

Intramural Funding Opportunities

Massey Cancer Center
American Cancer Society Institutional Research Grant (IRG)
Deadline: 07/01/2019

About: The American Cancer Society IRG are awarded to junior faculty to pursue basic, pre-clinical, clinical and cancer-control research studies (including but not limited to health services, psychosocial/behavioral, epidemiologic and health policy/outcome cancer research). These grants are intended for new investigators who are within six years of their first academic appointment who do not have an active, nationally competitive research grant.

Period of Support: 1 year
Funds/Direct Costs: Up to $30,000 for entire period
Internal Contact: Olivia Patterson
(804) 628-3400
opatterson@vcu.edu